Clinical Trials Browser

Phase 3 × disitamab vedotin × 1 year × Clear all

NCT05911295 2026-04-20

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Phase 3 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07315750 2026-01-21

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase 3 Recruiting

Gastrointestinal

Stomach Neoplasms